Sanofi Expands Cancer Treatment Offerings with $9.5 Billion Blueprint Acquisition

Cambridge, Monday, 2 June 2025.
Sanofi’s acquisition of Blueprint Medicines for $9.5 billion boosts its oncology and precision medicine portfolio, marked by a 27% surge in Blueprint’s stock.